Professor Keith Harding
Prosiectau fel Prif Ymchwiliwr
1 o 10
- A 6 month prospective, randomized, double blind, placebo-controlled, parallel group, multiple centre trial to evaluate the efficacy and safety of fragmin in the treatment of chronic neuroischaemic foot ulcers in diabetic patients (17.06.2008 - 31.12.2010)
- Agreement between the Wound Healing Research Unit and 3M Laboratories (Europe) Ltd - Skin Care Agreement (01.05.2001 - 30.11.2009)
- A method for sampling wounds for exudate, enabling remote diagnosis of protease and other biological component activity in chronic wounds (01.09.2009 - 31.01.2012)
- An open prospective randomised multi-centre clinical evaluation to compare ALLEVYN gentle border with Mepilex border in the management of exuding chronic and acute wounds (22.04.2009 - 21.04.2011)
- An open randomised comparative study to evaluate the performance of aquacel extra in venous leg ulcers (01.04.2012 - 31.10.2012)
Prosiectau fel Cyd-Ymchwiliwr
1 o 4
- Accelerate East (01.06.2018 - 31.12.2022)
- Accelerate West (01.06.2018 - 31.12.2022)
- Controlled and targeted delivery of potassium permanganate microparticles to wounds utilising the Permipatch technology (13.09.2015 - 31.08.2016)
- Development of a chemiluminescent-based test for miR-21 to investigate its potential as a diagnostic marker in chronic wound management (01.08.2014 - 31.08.2015)
- Development of a wound healing prognostic indicator (01.01.2011 - 31.07.2012)
Thomson Reuters Deutschland GmbH
Zur Giesserei 2
D-76227 Karlsruhe | Germany